Alkermes Plc (NASDAQ:ALKS) has begun studies on its cancer immunotherapy drug ALKS 4230. Formerly referred to as RDB 1450, this drug will be studied for its immunological- pharmacodynamic effects in the treatment of solid tumors.
Alkermes plc (Nasdaq: ALKS) announced the initiation of a phase 1 clinical study of the company's immuno-oncology drug candidate, ALKS 4230 (formerly referred to as RDB 1450), a novel Selective Effector Cell Activator (SECA™) protein designed for ...
Alkermes plc (NASDAQ:ALKS) has a daily sentiment score of -0.203. This score is given by Alpha One, which uses its self-designed algorithm to identify market sentiment on the stock after studying the published content on the web.
CVS Health Corporation (NYSE:CVS) went lower by -0.01% to close at $ 96.94. The company exchanged total volume of 4.44 million shares throughout course of last trade however it holds an average trading capacity of 4.31 million shares.